| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
| Company Name: |
BOC Sciences |
| Tel: |
16314854226 |
| Email: |
info@bocsci.com |
BMS-795311
(BMS795311) manufacturers
- BMS-795311
-
- $1970.00
-
2026-05-11
- CAS:939390-99-5
- Purity:
- Supply Ability: 10g
|
| | BMS-795311
(BMS795311) Basic information |
| Product Name: | BMS-795311
(BMS795311) | | Synonyms: | BMS-795311
(BMS795311);N-[(1R)-1-[3-(Cyclopropyloxy)-4-fluorophenyl]-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamide;Benzamide, N-[(1R)-1-[3-(cyclopropyloxy)-4-fluorophenyl]-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)- | | CAS: | 939390-99-5 | | MF: | C33H23F10NO3 | | MW: | 671.52 | | EINECS: | | | Product Categories: | | | Mol File: | 939390-99-5.mol |  |
| | BMS-795311
(BMS795311) Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Soluble in DMSO |
| | BMS-795311
(BMS795311) Usage And Synthesis |
| Uses | BMS-795311 is a potent and orally bioavailable inhibitor of cholesteryl ester transfer protein (CETP), with IC50s of 4 nM in an enzyme-based scintillation proximity assay (SPA) and 0.22 μM in a human whole plasma assay (hWPA), respectively[1]. | | in vivo | BMS-795311 (1-3 mg/kg; oral administration) inhibits plasma CE transfer activity in human CETP (hCETP)/apoB-100 dual transgenic (Tg) mice[1].
BMS-795311 (3-10 mg/kg; p.o. for 3 days) increases high density lipoprotein-cholesterol (HDL-C) content[1].
BMS-795311 (8 mg/kg, i.v.) has no eect on mean, systolic, or diastolic blood pressure, heart rate, or locomotor activity in rat telemetry studies[1].
BMS-795311 exhibits reasonable oral bioavailability (mice 37%, rats 37%, monkeys 20%, dogs 5%) and Cmax (mice 5.3, rats 17, monkeys 1.7, dogs 0.43 ng/mL) following oral administration (mice 10, rats 10, monkeys 5, dogs 5 mg/kg)[1].
BMS-795311 exhibits terminal elimination half-lives (mice 6, rats 7, monkeys >18, dogs 10 h) due to low plasma clearance (2.0, 0.9, 0.9, and 1.4 mL/min/kg respectively) combined with little volumes of distribution (0.8, 0.4, 0.9, and 0.6 L/kg respectively) following intravenous administration (mice 5, rats 1, monkeys 4, dogs 1 mg/kg)[1]. | Animal Model: | hCETP/apoB-100 dual Tg mice[1] | | Dosage: | 1, 3 mg/kg | | Administration: | Oral administration | | Result: | Inhibited CETP activity at a dose of 1 mg/kg at the 8 h time point. |
| Animal Model: | Moderately fat-fed hamsters[1] | | Dosage: | 3, 10 mg/kg | | Administration: | Oral administration for 3 days | | Result: | Increased plasma high density lipoprotein-cholesterol (HDL-C) content by 45% when dosed at 10 mg/kg. |
| | References | [1] Jennifer XQ, et, al. Triphenylethanamine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors: Discovery of N-[(1R)-1-(3-Cyclopropoxy-4-fluorophenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamide (BMS-795311). J Med Chem. 2015 Nov 25; 58(22): 9010-26. DOI:10.1021/acs.jmedchem.5b01363 |
| | BMS-795311
(BMS795311) Preparation Products And Raw materials |
|